{"filings":[{"id":1194800,"accession_number":"0001193125-26-277513","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2026-06-22T20:05:37+00:00","items":["5.02","5.07"],"status":"ready","headline":"Director Michelle Doig resigns; shareholders elect two Class I directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Michelle Doig resigned as Class I director upon completion of her term on June 16, 2026; resignation not due to any disagreement.","Shareholders elected Peter Lebowitz (31,822,504 votes for) and Frank McCormick (25,654,119 votes for) as Class I directors.","Ratification of Deloitte & Touche LLP as independent auditor for FY 2026 approved with 34,535,875 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":42522,"accession_number":"0001193125-26-219801","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2026-05-12T21:07:04+00:00","items":["2.02","9.01"],"status":"ready","headline":"BBOT Q1 net loss widens to $42.1M; cash $388.9M funds ops into 2028; pipeline shows early efficacy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $42.1M vs $22.1M YoY; R&D spend $39.8M on advancing three RAS programs.","Cash, equivalents and marketable securities $388.9M as of March 31, 2026; runway into 2028.","BBO-8520 monotherapy ORR 65% in KRAS G12C NSCLC; BBO-11818 partial response in pancreatic cancer.","BBO-10203 achieved target engagement with no hyperglycemia; clinical benefit in CRC and HR+ BC.","Pedro Beltran appointed CEO, Idan Elmelech COO effective April 20, 2026; Neil Kumar Executive Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":-526.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96434,"accession_number":"0001193125-26-191512","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BridgeBio Oncology enters consulting agreement with former CEO Eli Wallace; equity vesting continues for 12 months","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Wallace provides R&D advisory services for 12 months retroactive to April 21, 2026.","Compensation: continued vesting of outstanding equity awards subject to service through each vesting date.","Vested stock options exercisable up to 2 years after consulting termination or original expiry, whichever earlier.","Wallace also receives Tier 1 severance benefits under the Executive Severance Plan via Separation Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96433,"accession_number":"0001193125-26-170888","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BBOT appoints Pedro Beltran as CEO, Idan Elmelech as COO, and Neil Kumar as Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pedro Beltran, previously CSO, succeeds Eli Wallace as President and CEO effective April 20, 2026; also named Class III director.","Idan Elmelech, former SVP Strategy, promoted to COO, principal financial officer; Marc Cobo becomes principal accounting officer.","CFO Uneek Mehra departs April 30, 2026; no disagreement cited.","Neil Kumar appointed Executive Chairman; founder figure to guide next development phase.","Eli Wallace transitions to Senior Adviser; Board thanks him for service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110318,"accession_number":"0001193125-26-126493","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BridgeBio Oncology appoints Peter Lebowitz as independent director; NCG, Compensation committees; option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased to nine; Lebowitz appointed as Class I director.","Lebowitz is independent and serves on NCG and Compensation committees.","Received one-time option for 63,350 shares at $8.72/share (closing price on 3/24/2026).","Standard indemnification agreement executed covering expenses from board service.","No disclosable transactions under Reg S-K Item 404(a) involving Lebowitz."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110317,"accession_number":"0001193125-26-093997","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BBOT reports Q4 net loss $38.8M; cash runway into 2028; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $38.8M (vs $19.7M in Q4 2024); full year net loss $134M (vs $74.3M).","Cash and equivalents $425.5M; expected to fund operations into 2028.","R&D expenses Q4 $38.1M (vs $19.5M); G&A $5.3M (vs $2.3M); increases driven by clinical and manufacturing.","BBO-8520 monotherapy 65% ORR in KRAS G12C NSCLC; BBO-11818 first confirmed PR in PDAC; BBO-10203 no hyperglycemia.","Clinical data readouts across all three programs expected in H2 2026; internal combinations opening later in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110316,"accession_number":"0001193125-26-005425","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BBOT reports 65% ORR for BBO-8520, first panKRAS response in PDAC, no hyperglycemia with BBO-10203","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BBO-8520 monotherapy: 65% ORR (11/17), 66% 6-month PFS, including one complete response; all 5 STK11/KEAP1 co-mutant patients achieved PR.","BBO-8520 + pembrolizumab: all 8 evaluable patients had tumor reduction; 3/3 front-line and 2/5 prior KRAS G12C inhibitor patients achieved PR.","BBO-11818 panKRAS inhibitor: first monotherapy PR in pancreatic ductal adenocarcinoma (44% tumor reduction); dose-proportional exposure covering G12D/G12V at 600 mg BID.","BBO-10203 RAS:PI3Kα breaker: no hyperglycemia of any grade, no baseline HbA1c/glucose restrictions; 500 mg QD selected for expansion; combination studies initiated.","Combination studies of BBO-8520, BBO-11818, and BBO-10203 with each other and with standard-of-care expected to open in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126915,"accession_number":"0001193125-25-277601","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BBOT Q3 2025 net loss $44.8M; cash $468.3M funds operations into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $44.8M vs $17.3M in Q3 2024; R&D expenses $35.1M, G&A $14.1M.","Cash, equivalents and marketable securities $468.3M; runway expected into 2028.","Closed SPAC business combination with Helix Acquisition Corp II on Aug 11, 2025; began trading on Nasdaq as BBOT.","Appointed Uneek Mehra as CFO in July 2025.","Three Phase 1 trials advancing (BBO-8520, BBO-10203, BBO-11818); initial clinical data readouts expected in 2026."],"consensus_eps_estimate":-0.3976,"consensus_eps_actual":-6.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143702,"accession_number":"0001213900-25-075190","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["1.01","2.01","3.02","9.01","4.01","3.03","5.03","8.01","5.01","5.02","5.05","5.06","7.01"],"status":"ready","headline":"BridgeBio Oncology closes SPAC merger; raises $260.9M PIPE, $381.8M total gross proceeds","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closing on Aug 11, 2025: Helix domesticated to Delaware, merged with BBOT subsidiary; new name BridgeBio Oncology Therapeutics, ticker BBOT.","PIPE of $260.9M (24.3M shares at $10.7173) plus $120.9M trust; $76.3M redeemed by 7.1M public shares.","Pro forma shares: ~79.2M outstanding (excluding options); ~61.1M shares (77.2%) subject to registration rights.","Lock-up: Helix insiders 1 year; BBOT employees below VP 6 months; other BBOT holders 1 year.","Equity plans approved: 2025 Incentive Plan (5.37M shares + evergreen) and ESPP (0.9M shares + evergreen)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143705,"accession_number":"0001213900-25-072312","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Helix retains ~$120M trust (60%+) after redemptions; PIPE adds ~$261M for BBOT deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Retained ~$120M in trust (~60%+ of original) after redemptions; 2nd lowest biotech de-SPAC redemption rate since 2022.","Total expected gross proceeds ~$382M including ~$261M from PIPE led by Cormorant Asset Management and other investors.","Business combination with BridgeBio Oncology Therapeutics (BBOT) expected to close expeditiously, subject to conditions.","Redemption request deadline was July 31, 2025; the low redemption rate signals shareholder support for the deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143704,"accession_number":"0001213900-25-071392","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Helix shareholders approve all proposals for business combination with BridgeBio Oncology Therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Business Combination Proposal approved: 17.3M FOR, 2.1M AGAINST (82.55% quorum).","Domestication to Delaware, new charter and bylaws, name change to BridgeBio Oncology Therapeutics Inc. approved.","All 9 director nominees elected unanimously with 19.4M votes each; effective at closing.","2025 Stock Option and Incentive Plan and Employee Stock Purchase Plan both approved by shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143703,"accession_number":"0001213900-25-062955","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BridgeBio Oncology SPAC merger S-4 effective; shareholder vote set for Aug 4, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["SEC declared Registration Statement on Form S-4 effective for Helix/BBOT business combination.","Extraordinary General Meeting of Helix shareholders scheduled for August 4, 2025.","Record date for shareholders entitled to vote is June 30, 2025.","Business combination expected to close in August 2025, subject to conditions.","Post-close company will be renamed BridgeBio Oncology Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179981,"accession_number":"0001213900-25-018997","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Helix Acquisition Corp. II to merge with BridgeBio Oncology Therapeutics in $461M deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Equity value of $461M; BBOT stockholders to receive shares of PubCo common stock.","PIPE investments of ~$260M committed, including $75M from Cormorant; minimum $400M cash required at close.","Closing expected after SEC effectiveness, shareholder approvals, and Nasdaq listing; drop-dead date Oct 31, 2025.","Sponsor to forfeit shares if Helix Closing Cash < $400M; non-redemption agreements cover 450,900 Class A shares.","Lock-up on Sponsor and existing Helix investors' shares for one year post-Closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179980,"accession_number":"0001213900-25-018334","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BBOT to merge with Helix II SPAC in $450M deal; public listing expected Q3 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total proceeds ~$450M from Helix trust (~$196M) and $260M PIPE led by Cormorant, including Deerfield, Novo Holdings, Wellington.","Combined company to be named BridgeBio Oncology Therapeutics (BBOT), trading on Nasdaq under ticker BBOT.","Pro forma equity value ~$949M at $10.36/share assuming no redemptions; BBOT shareholders roll 100% equity.","Lead programs: BBO-8520 (KRAS G12C Phase 1), BBO-10203 (RAS-PI3Kα Phase 1), BBO-11818 (pan-KRAS Phase 1 starting H1 2025).","Transaction approved by both boards; expected close Q3 2025, subject to stockholder approvals and conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179979,"accession_number":"0001213900-25-011454","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Helix Acquisition Corp. II appoints Albert A. Holman, III to its Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Albert A. Holman, III appointed on Feb 8, 2025 as Class III independent director.","Holman brings life sciences investment banking experience; will serve on Audit Committee.","Sponsor transferred 30,000 Class B ordinary shares to Holman in connection with appointment.","Holman executed standard SPAC Letter Agreement and Joinder to Registration Rights Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250458,"accession_number":"0001213900-24-015329","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Helix Acquisition Corp. II completes $184M IPO and $5M private placement; trust funded","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 18.4M Class A shares at $10.00 each included full exercise of 2.4M over-allotment shares.","Private sale of 509,000 Class A shares to sponsor Helix Holdings LLC at $10.00/share, gross $5.09M.","Net proceeds of $184M (including $5.52M deferred underwriting fee) deposited into trust account.","Audited balance sheet at Feb 13, 2024: $184M in trust, $2.5M cash, $3.2M shareholders' deficit.","SPAC focused on healthcare; must complete initial business combination within 24 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250457,"accession_number":"0001213900-24-013637","cik":1869105,"company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["1.01","3.02","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Helix Acquisition Corp. II closes $184M IPO, including full over-allotment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed IPO of 18.4M Class A shares at $10.00 each; gross proceeds $184M.","Underwriter exercised over-allotment option in full for additional 2.4M shares.","Sponsor purchased 509,000 private placement shares at $10.00 for $5.09M.","Total $184M placed in trust; must complete business combination within 24 months.","Appointed Mark C. McKenna and John Schmid as independent directors; charter amended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":689722121.9155921,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}